Table 3.

Cox proportional hazards regression for progression-free survival and overall survival of patients with initial brain metastases.

		Progression-free survival		Overall survival
		HR (95% CI)	p value	HR (95% CI)	p value
Age	>60 versus <60	1.13 (0.59–2.15)	0.709	1.04 (0.50–2.19)	0.910
Sex	Male versus female	1.70 (0.94–3.09)	0.081	2.48 (1.20–5.16)	0.015
ECOG PS	⩾2 versus <2	1.81 (0.93–3.52)	0.082	2.59 (1.18–5.71)	0.018
Tumor size	>3 cm versus <3 cm	3.16 (1.17–8.53)	0.023	5.52 (1.12–27.1)	0.035
Nodal involvement	Positive versus negative	0.80 (0.25–2.51)	0.698	0.69 (0.17–2.89)	0.616
Smoking	Positive versus negative	1.59 (0.68–3.73)	0.283	1.42 (0.57–3.57)	0.452
EGFR mutation	Del 19 versus others	1.63 (0.89–3.00)	0.114	0.91 (0.45–1.84)	0.784
Recurrence	Recurrence versus new diagnosis	1.61 (0.30–8.62)	0.577	1.18 (0.17–8.09)	0.865
Treatment	Erlotinib versus gefitinib	0.56 (0.27–1.14)	0.108	0.92 (0.39–2.14)	0.840
	Afatinib versus gefitnib	0.61 (0.30–1.23)	0.168	1.16 (0.50–2.71)	0.726

ECOG, Eastern Cooperative Oncology Group; CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; PS, performance status.